Therefore, we suggest that both a lung biopsy and the test of PR3-ANCA (or C-ANCA) should be serially performed in PM/DM patients who have PR3-ANCA (or C-ANCA) and only ILD among systemic manifestations. This evidence concerns the gene PRTN3 and polymyositis.